Crossmark

A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial

Crossref DOI link: https://doi.org/10.1186/s13063-021-05180-1

Published Online: 2021-04-13

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Akova, Murat http://orcid.org/0000-0002-6904-9473
Unal, Serhat
Funding

Funding for this research was provided by:

Turkish Health Institutes Association
License Information

Text and Data Mining valid from 2021-04-13

Version of Record valid from 2021-04-13
More Information

Article History

Received: 5 March 2021

Accepted: 10 March 2021

First Online: 13 April 2021

Declarations

:

: This study was reviewed and approved by the Clinical Investigations Ethics Committee of Hacettepe University (No: 2020/10-26 and Date: 16.07.2020). Signed informed consents of all participants will be obtained.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below